The government is aiming to cap trade margins on anti-cancer medications at 30%. An expert committee has been tasked with compiling a report by October 14 on eligible drugs. The move targets the excessive mark-ups currently averaging 170% for various non-scheduled anti-cancer medicines, potentially saving around Rs 2,500 crore and enhancing affordability for patients.